PMID: 9432048Jan 31, 1998Paper

The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation

British Journal of Haematology
P RaananiN C Cross

Abstract

We have assessed the molecular response of 30 consecutive patients with chronic myeloid leukaemia (CML) treated for relapse after allogeneic bone marrow transplantation (BMT) by donor leucocyte transfusions (DLT). Response was evaluated by qualitative nested and quantitative competitive RT-PCR for BCR-ABL mRNA at various time intervals before and after DLT. The probability of attaining molecular remission at 2 years was 61% (95% CI 42-78%). Disease state at the time of DLT was significantly associated with response: molecular remission was achieved for 9/10 (90%) patients treated early (cytogenetic or molecular relapse) compared to only 8/20 (40%) patients treated late (haematological relapse; P = 0.009). The Kaplan-Meier estimates of molecular remission at 2 years post DLT for patients treated in early or late relapse were 86.6% and 47.3% respectively (P = 0.004). The median time interval from DLT to molecular remission was 11.0 months (range 2.5-32). Molecular remissions were durable for most (15/17) patients (median follow-up 21.2 months; range 0-55). Two patterns of molecular response were found: a very rapid decline after an initial lag phase or a more gradual decline over a period of several months. We conclude that molec...Continue Reading

Citations

Oct 17, 2003·Hematology/oncology Clinics of North America·Alan S Wayne, A J Barrett
Apr 25, 2003·Critical Reviews in Oncology/hematology·Shimon SlavinReuven Or
Mar 22, 2002·The Lancet Oncology·T SzczepańskiJ J van Dongen
Feb 5, 2002·The Journal of Molecular Diagnostics : JMD·Adam Bagg
Nov 5, 1999·Current Opinion in Hematology·F Dazzi, J Goldman
Aug 15, 1998·Vox Sanguinis·C V Prowse
Feb 27, 2015·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Felix SchmidtStephan Fricke
Apr 2, 2002·Best Practice & Research. Clinical Haematology·K S Peggs, S Mackinnon
Mar 1, 1994·Blood Reviews·J M Goldman
May 4, 2002·Best Practice & Research. Clinical Haematology·Andreas Hochhaus
Nov 5, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicolaus KrögerMichael R Bishop
Dec 13, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·R OrM Y Shapira
Jan 13, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Michael R BishopSergio Giralt
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John E LevineRobert H Collins
Jul 4, 2001·Bone Marrow Transplantation·R ChamplinS Giralt
Oct 20, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard D PressMichael W N Deininger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.